Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 2
2017 2
2018 5
2019 9
2020 8
2021 5
2022 8
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean melanin caps (30 results)?
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.
Fotia G, Stellato M, Guadalupi V, Sepe P, Claps M, Giannatempo P, Bottiglieri A, Rametta A, Taglialatela I, Vela C, Procopio G, Verzoni E. Fotia G, et al. Among authors: claps m. Curr Oncol Rep. 2023 Jun;25(6):671-677. doi: 10.1007/s11912-023-01395-4. Epub 2023 Mar 31. Curr Oncol Rep. 2023. PMID: 37000341 Review.
Biomarker-driven immunotherapy for precision medicine in prostate cancer.
Ottini A, Sepe P, Beninato T, Claps M, Guadalupi V, Verzoni E, Giannatempo P, Baciarello G, de Braud F, Procopio G. Ottini A, et al. Among authors: claps m. Per Med. 2022 Jan;19(1):51-66. doi: 10.2217/pme-2021-0079. Epub 2021 Dec 7. Per Med. 2022. PMID: 34873959 Review.
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V, De Giorgi U, Bimbatti D, Nolè F, Carrozza F, Buti S, Iacovelli R, Ciccarese C, Masini C, Baldessari C, Doni L, Cusmai A, Gernone A, Scagliarini S, Pignata S, de Braud F, Verzoni E. Procopio G, et al. Among authors: claps m. Tumori. 2023 Feb;109(1):129-137. doi: 10.1177/03008916221138881. Epub 2022 Nov 29. Tumori. 2023. PMID: 36447337 Free PMC article. Clinical Trial.
The role of metastasectomy in advanced renal cell carcinoma.
Apollonio G, Raimondi A, Verzoni E, Claps M, Sepe P, Pagani F, Ratta R, Montorsi F, De Braud FGM, Procopio G. Apollonio G, et al. Among authors: claps m. Expert Rev Anticancer Ther. 2019 Jul;19(7):603-611. doi: 10.1080/14737140.2019.1625772. Epub 2019 Jun 8. Expert Rev Anticancer Ther. 2019. PMID: 31159619 Review.
The emerging role of PARP inhibitors in prostate cancer.
Stellato M, Guadalupi V, Sepe P, Mennitto A, Claps M, Zattarin E, Verzoni E, Valdagni R, De Braud FG, Santini D, Tonini G, Procopio G. Stellato M, et al. Among authors: claps m. Expert Rev Anticancer Ther. 2020 Aug;20(8):715-726. doi: 10.1080/14737140.2020.1797497. Epub 2020 Aug 6. Expert Rev Anticancer Ther. 2020. PMID: 32758032 Review.
Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy.
Bottiglieri A, Sepe P, Stellato M, Pircher C, Fotia G, Leone AG, Guadalupi V, Claps M, Giannatempo P, Verzoni E, Procopio G. Bottiglieri A, et al. Among authors: claps m. Cancer Manag Res. 2022 Oct 21;14:3071-3081. doi: 10.2147/CMAR.S360441. eCollection 2022. Cancer Manag Res. 2022. PMID: 36275783 Free PMC article. Review.
40 results